Abbvie announced that the FDA has approved Rinvoq (upadacitinib) for use in adults with active ulcerative colitis (after failing TNFi); approval based on 3 endoscopic UC trials. Starting dose is 45 mg/d, then maintain w/ 15 mg (some can get 30 mg) https://t.co/ZUbnkR7LMY https://t.co/dE1JkxzkSz